CNTA · Centessa Pharmaceuticals plc
$40.50
+0.00 (+0.00%)
At close · Jun 29
Market Cap
$6.27B
Shares
154.73M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Saurabh Saha | CEO | $11,877,244 |
| Stephen Kanes | Chief Medical Officer and Head of R&D | $6,812,680 |
| John Crowley | CFO | $3,842,835 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Saurabh Saha | CEO | $5,563,120 |
| John Crowley | CFO | $4,120,748 |
| Iqbal Hussain | General Counsel | $2,046,325 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Saurabh Saha | CEO | $2,705,874 |
| Antoine Yver | Chairman | $1,380,739 |
| David Grainger | Chief Innovation Officer | $1,363,599 |
| David Chao | Chief Administrative Officer | $1,317,905 |
| Iqbal Hussain | General Counsel | $1,181,713 |
| John Crowley | CFO | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Saurabh Saha | CEO | $9,612,230 |
| Gregory Weinhoff | CFO | $3,309,069 |
| David Chao | Chief Administrative Officer | $3,309,069 |
| Antoine Yver | Chairman | $2,517,232 |
| David Grainger | Chief Innovation Officer | $2,447,805 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Antoine Yver | Chairman | $17,127,519 |
| Saurabh Saha | CEO | $16,068,587 |
| Gregory Weinhoff | CFO | $4,043,608 |
| David Chao | Chief Administrative Officer | $3,962,067 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Saurabh Saha | CEO | — |
| Gregory Weinhoff | CFO | — |
| Antoine Yver | Chairman | — |